Antibody-drug conjugates (ADCs) are potent therapeutic tools with promising efficacy in cancer treatment. Some ADCs, particularly those with microtubule-inhibiting payloads, have been linked to ocular side effects. For instance, Blenrep and Mirvetuximab soravtansine-gynx are associated with corneal microcyst-like epithelial changes, keratopathy, blurred vision, dry eye, and photophobia. Tivdak and Datroway, targeting tissue factor and TROP2, […]
